Botulinum toxin A does not alter capsaicin-induced pain perception in human skin

Journal of the Neurological Sciences

Volumn 260, Issue 1-2, 2007, Pages 38-42

  Schulte Mattler, Wilhelm J ^a   Opatz, Oliver ^a   Blersch, Wendelin ^a   May, Arne ^a   Bigalke, Hans ^b   Wohlfahrt, Kai ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Botulinum toxin; Capsaicin; Inflammation; Nociception; Quantitative sensory testing; Thermal pain

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ALLODYNIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROSTIMULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROGENIC INFLAMMATION; NOCICEPTION; NORMAL HUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN; TEMPERATURE SENSITIVITY;

ADULT; ANALGESICS, NON-NARCOTIC; BOTULINUM TOXIN TYPE A; CAPSAICIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; NEUROTOXINS; NOCICEPTORS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PLACEBOS; PROSPECTIVE STUDIES; RECEPTORS, SENSORY; SKIN;

EID: 34547655570     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.03.023     Document Type: Article

References (24)

1. Scott A.B., Rosenbaum A., and Collins C.C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12 (1973) 924-927
2. Wohlfarth K., Goeschel H., Frevert J., Dengler R., and Bigalke H. Botulinum A toxins: units versus units. Naunyn-Schmiedebergs Arch Pharmacol 355 (1997) 335-340
3. Greene P., Kang U., Fahn S., Brin M., Moskowitz C., and Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40 (1990) 1213-1218
4. Hyman N., Barnes M., Bhakta B., Cozens A., Bakheit M., Kreczy-Kleedorfer B., et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68 (2000) 707-712
5. Wissel J., Kanovsky P., Ruzicka E., Bares M., Hortova H., Streitova H., et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 248 (2001) 1073-1078
6. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365 (1993) 160-163
7. Bigalke H., and Shoer L.F. Clostridial neurotoxins. Handb. Exp. Pharmacol. 145 (2000) 407-443
8. Heckmann M., Ceballos-Baumann A.O., and Plewig G. Botulinum toxin A for axillary hyperhidrosis. N Engl J Med 344 (2001) 488-493
9. Yokosawa N., Suga K., Kimura K., Tsuzuki K., Fujii N., Oguma K., et al. Exogenous zinc ion is required for inhibitory activity of botulinum neurotoxin C1 against norepinephrine release and its endopeptidase activity toward substance P. Biochem Mol Biol Int 32 (1994) 455-463
10. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44 (2000) 106-109
11. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
12. Schmelz M., Luz O., Averbeck B., and Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neurosci Lett 230 (1997) 117-120
13. Gobel H., Heinze A., Heinze-Kuhn K., and Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91 (2001) 195-199
14. Kelm S., Gerats G., Chalkiadaki A., and Hefter H. Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72 (2001) 302-306
15. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
16. Blersch W., Schulte-Mattler W.J., Przywara S., May A., Bigalke H., and Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205 (2002) 59-63
17. Kramer H.H., Angerer C., Erbguth F., Schmelz M., and Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250 (2003) 188-193
18. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H.G., et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61 (2003) 940-944
19. Koppert W., Ostermeier N., Sittl R., Weidner C., and Schmelz M. Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 85 (2000) 217-224
20. Yarnitsky D. Quantitative sensory testing. Muscle Nerve 20 (1997) 198-204
21. Kaube H., Katsarava Z., Kaufer T., Diener H., and Ellrich J. A new method to increase nociception specificity of the human blink reflex. Clin Neurophysiol 111 (2000) 413-416
22. Kilo S., Schmelz M., Koltzenburg M., and Handwerker H.O. Different patterns of hyperalgesia induced by experimental inflammation in human skin. Brain 117 (1994) 385-396
23. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405 (2000) 183-187
24. Foster L., Clapp L., Erickson M., and Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56 (2001) 1290-1293